Viatris (VTRS) Receivables (2019 - 2026)
Viatris (VTRS) posted Receivables of $3.7 billion for Q2 2026, up 2.69% on a QoQ basis from $3.6 billion in Q1 2026, and down 1.36% year-over-year from $3.7 billion in Q2 2025.
Analysis
Viatris (VTRS) Receivables (2019 - 2026) Analysis & Trends
Viatris has reported Receivables for 8 years, with the latest figure at $3.7 billion in Q2 2026.
- On a quarterly basis, Receivables fell 1.36% year-over-year to $3.7 billion in Q2 2026; TTM through Jun 2026 was $3.7 billion, a 1.36% decrease from a year earlier, with the FY2025 full-year figure at $3.5 billion, down 7.49% from the prior year.
- Receivables was $3.7 billion for Q2 2026 at Viatris, up from $3.6 billion in the prior quarter.
- The five-year high for Receivables was $4.6 billion in Q1 2022, with the low at $3.5 billion in Q4 2025.
- Average Receivables over 5 years is $4.1 billion, with a median of $4.0 billion recorded in 2023.
- The sharpest annual moves came in 2022 and 2024: Receivables fell 20.86% in 2022, then increased 12.61% in 2024.
- Over 5 years, Receivables stood at $4.4 billion in 2022, then advanced by 4.37% to $4.6 billion in 2023, then fell by 17.69% to $3.8 billion in 2024, then fell by 7.49% to $3.5 billion in 2025, then climbed by 5.35% to $3.7 billion in 2026.
- The last three Receivables figures came in at $3.7 billion (Q2 2026), $3.6 billion (Q1 2026), and $3.5 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 3.49 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 3.67 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 1.06 Bn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 1.61 Bn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 2.26 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 211.59 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 274.47 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 145.76 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 23.27 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.67 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Dec 31, 2025 | 3.49 Bn |
| Sep 30, 2025 | 3.83 Bn |
| Jun 30, 2025 | 3.72 Bn |
| Mar 31, 2025 | 3.67 Bn |
| Dec 31, 2024 | 3.77 Bn |
| Sep 30, 2024 | 4.58 Bn |
| Jun 30, 2024 | 4.45 Bn |
| Mar 31, 2024 | 4.47 Bn |
| Dec 31, 2023 | 4.58 Bn |
| Sep 30, 2023 | 4.25 Bn |
| Jun 30, 2023 | 4.09 Bn |
| Mar 31, 2023 | 3.97 Bn |
| Dec 31, 2022 | 4.39 Bn |
| Sep 30, 2022 | 3.84 Bn |
| Jun 30, 2022 | 4.29 Bn |
| Mar 31, 2022 | 4.63 Bn |
| Dec 31, 2021 | 4.76 Bn |
| Sep 30, 2021 | 4.85 Bn |